mortality/aging
• more than half of mice
|
immune system
N |
• surviving mice exhibit no auto-immune disease symptoms up to 4 months of age
• mice exhibit normal numbers of regulatory T cells in the thymus and spleen
|
• DSS-treated mice exhibit accelerated body weight loss, severe intestinal inflammation, increased Th1 cells and attenuated increase of regulatory T cells in the colon and cecum lamina propria compared with control mice
|
• increased under Th1-, Th17- and induced regulatory T cell-skewing conditions
|
• reduced under Th17-skewing conditions
|
• CD44highCD62Llow-activated and IFN-gamma CD4+ T cells
|
• in DSS-treated mice
|
• reduced regulatory T cell differentiation under induced regulatory T cell-skewing conditions
|
• in DSS-treated mice
|
digestive/alimentary system
• DSS-treated mice exhibit accelerated body weight loss, severe intestinal inflammation, increased Th1 cells and attenuated increase of regulatory T cells in the colon and cecum lamina propria compared with control mice
|
growth/size/body
• accelerated in DSS-treated mice
|
hematopoietic system
• increased under Th1-, Th17- and induced regulatory T cell-skewing conditions
|
• reduced under Th17-skewing conditions
|
• CD44highCD62Llow-activated and IFN-gamma CD4+ T cells
|
• in DSS-treated mice
|
• reduced regulatory T cell differentiation under induced regulatory T cell-skewing conditions
|
• in DSS-treated mice
|